MedPath

Novel MRI Contrast Agent Shows Promise in Breast Cancer Imaging: Clinical Results to be Published in Investigative Radiology

Spago Nanomedical's pegfosimer manganese demonstrated successful contrast enhancement in breast cancer MRI imaging with acceptable safety profile in the SPAGOPIX-01 clinical trial. The findings, set to be published in Investigative Radiology, mark a significant advancement in precision medical imaging for cancer diagnostics.

Spago Nanomedical AB has achieved a significant milestone in medical imaging advancement with the acceptance of their clinical trial results for publication in the prestigious journal Investigative Radiology. The study, focusing on their novel contrast agent pegfosimer manganese, demonstrates promising results in enhancing magnetic resonance imaging (MRI) visualization of breast cancer tumors.
The manuscript, titled "Safety, Tolerability, Efficacy and Pharmacokinetics of Pegfosimer manganese (SN132D) for Contrast Enhanced MRI of Breast Cancer," will be featured in the September 2025 issue, highlighting the product's clinical potential in cancer diagnostics.

Clinical Trial Outcomes

The SPAGOPIX-01 trial (NCT04080024) revealed that pegfosimer manganese, previously known as SN132D, successfully achieved its primary objectives. The contrast agent demonstrated:
  • Acceptable safety profile in study participants
  • Clinically relevant contrast enhancement in primary breast cancer tumors
  • Potential application in improving MRI precision for cancer detection

Broader Applications and Development

Beyond breast cancer imaging, the SpagoPix development program has shown promising results in other applications:
  • Successful contrast enhancement observed in endometriosis lesions during a Phase IIa study (NCT05664828)
  • Potential for improved visualization of various tumors and lesions
  • Development of a selective contrast agent for more precise diagnostic imaging
"A publication in one of the leading scientific journals in the medical imaging field is a strong validation of the extensive clinical development work behind the SpagoPix program," stated Mats Hansen, CEO of Spago Nanomedical. "The publication also supports our ongoing business development work aimed at finding potential partners or other solutions for further development of the program."

Future Development Strategy

The company has outlined its strategy for advancing the SpagoPix program:
  • Seeking partnerships or commercial collaborations for continued clinical development
  • Exploring licensing opportunities
  • Pursuing external financing options to support further research
The technology builds on Spago Nanomedical's platform of polymeric materials, designed to enable more precise treatment and diagnosis of cancer and other serious diseases. This advancement represents a significant step forward in the field of medical imaging, potentially offering healthcare providers enhanced diagnostic capabilities for more accurate disease detection and treatment planning.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Highlighted Clinical Trials

Efficacy of SN132D in Patients With Suspected Endometriosis

NCT05664828CompletedPhase 2
Spago Nanomedical AB
Posted 11/17/2022

Related Topics

Digoxin Reduces Circulating Tumor Cell Cluster Size in Metastatic Breast Cancer

A clinical trial demonstrated that digoxin, a cardiac drug, significantly reduced the size of circulating tumor cell (CTC) clusters in metastatic breast cancer patients.
The study found an average reduction of 2.2 cells per cluster after one week of low-dose digoxin treatment, decreasing the risk of metastasis.

FluoGuide's FG001 Demonstrates Positive Phase 2 Data in Head and Neck Cancer Surgery

FluoGuide's FG001, a novel imaging agent, has shown promising Phase 2 results in enhancing surgical accuracy for head and neck cancer patients.
The study, published in _Theranostics_, demonstrated 100% sensitivity in illuminating cancerous tissues with excellent tolerability across varying doses.

Pfizer Receives CDSCO Panel Approval for Phase III Trial of Rimegepant in India

Pfizer has been granted approval by the CDSCO panel in India to proceed with a Phase III clinical trial for Rimegepant.
The trial will evaluate Rimegepant's efficacy and safety in treating migraine, with a condition to enroll pediatric subjects weighing at least 40kg.

Radspherin Shows Promise in Colorectal Cancer Peritoneal Metastases: Phase 1/2a Data

Phase 1/2a study of Radspherin® demonstrates encouraging safety and efficacy in colorectal cancer patients with peritoneal metastases.
At 18 months, no peritoneal recurrences were observed in patients receiving the recommended dose of Radspherin® after cytoreductive surgery and HIPEC.

FDA Grants Fast Track Designation to 64Cu-SAR-bisPSMA for PSMA+ Prostate Cancer Imaging

The FDA granted Fast Track designation to 64Cu-SAR-bisPSMA, a novel PET imaging agent, for detecting prostate-specific membrane antigen (PSMA)-positive prostate cancer lesions with suspected metastases.
Phase 1 PROPELLER trial data showed a 100% primary prostate cancer detection rate by one reader and 85.7% by another, with greater uptake compared to the standard of care 68Ga-PSMA-11.

Pfizer's Ponsegromab Shows Promise in Treating Cancer Cachexia in Phase 2 Trial

Pfizer's ponsegromab met its primary endpoint in a Phase 2 trial, demonstrating a statistically significant increase in body weight compared to placebo in cancer cachexia patients.
The highest dose of ponsegromab (400 mg) led to a 5.61% mean increase in body weight at 12 weeks, along with improvements in appetite, cachexia symptoms, physical activity, and muscle mass.

Pfizer's Ponsegromab Shows Promise in Treating Cancer Cachexia in Phase 2 Trial

Pfizer's ponsegromab met its primary endpoint, demonstrating a statistically significant increase in body weight compared to placebo in cancer cachexia patients.
The highest dose of ponsegromab (400 mg) led to a 5.6% mean increase in body weight at 12 weeks, along with improvements in appetite and physical activity.

Pfizer's Ponsegromab Shows Promise in Treating Cancer Cachexia in Phase 2 Trial

Pfizer's ponsegromab met its primary endpoint in a Phase 2 trial, demonstrating a significant increase in body weight compared to placebo in cancer patients with cachexia.
The highest dose of ponsegromab resulted in a 5.61% mean increase in body weight after 12 weeks, along with improvements in appetite, physical activity, and muscle mass.

Singapore Team Uncovers Mechanisms of Gastric Cancer Peritoneal Metastasis, Advances Novel Therapy

Researchers in Singapore have identified key molecular mechanisms driving gastric cancer's spread to the peritoneum, the most common site of metastasis.
The study pinpointed genetic alterations and characteristics within the tumor microenvironment (TME) that facilitate peritoneal metastasis.

PSMA PET-CT Improves Prostate Cancer Metastasis Detection

PSMA PET-CT imaging proves more accurate than standard CT and bone scans in detecting prostate cancer metastasis, with 92% accuracy versus 65%.
The use of PSMA PET-CT led to a change in treatment plans for 28% of patients, compared to 15% with standard imaging, optimizing patient care.

Reference News

[1]
Spago Nanomedical Article on SPAGOPIX-01 Clinical Results Accepted for Publication in Investigative Radiology
morningstar.com · Jan 14, 2025

Spago Nanomedical announced the acceptance of a manuscript on pegfosimer manganese for publication in Investigative Radi...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy